Multiple Myeloma
Conditions
Brief summary
The primary and secondary endpoints, and their respective timepoints are defined in Table 33 of the Protocol
Detailed description
The primary and secondary endpoints, and their respective timepoints are defined in Table 33 of the Protocol, Incidence and severity of AEs, adverse laboratory results, and other safety parameters following TEC-TAL, JNJ-79635322-D, and JNJ-79635322-DR administration.
Interventions
DRUGDEXAMETHASONE
DRUGVELCADE 3.5 mg powder for solution for injection
DRUGJNJ-79635322
DRUGJNJ-64407564
DRUGPARACETAMOL
DRUGteclistamab
DRUGDIPHENHYDRAMINE
DRUGDEXAMETHASONE SODIUM PHOSPHATE
DRUGDARZALEX 1800 mg solution for injection
Sponsors
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary and secondary endpoints, and their respective timepoints are defined in Table 33 of the Protocol | — |
Secondary
| Measure | Time frame |
|---|---|
| The primary and secondary endpoints, and their respective timepoints are defined in Table 33 of the Protocol, Incidence and severity of AEs, adverse laboratory results, and other safety parameters following TEC-TAL, JNJ-79635322-D, and JNJ-79635322-DR administration. | — |
Countries
Austria, Germany, Greece, Italy, Netherlands
Outcome results
None listed